Mechanistic Insights into the Stimulant Properties of Novel Psychoactive Substances (NPS) and Their Discrimination by the Dopamine Transporter-In Silico and In Vitro Exploration of Dissociative Diarylethylamines.
Michelle A Sahai, Colin Davidson, Neelakshi Dutta, Jolanta Opacka-Juffry
Brain Sciences April 7, 2018 DOI: 10.3390/brainsci8040063 (opens in new tab) via PubMed
Summary
AI-generated from the abstractDiphenidine (DPH), a dissociative novel psychoactive substance, binds to the dopamine transporter in rat brain tissue and increases electrically-evoked dopamine efflux in the nucleus accumbens, indicating potential for addiction. In contrast, methoxphenidine (MXP) shows no significant effect on dopamine transporter binding or dopamine release. Computational modeling of five dissociative compounds confirms these differences and explains the atomic-level interactions within the dopamine transporter. Despite their chemical similarity, DPH, but not MXP, may have addictive liability through stimulant-like actions on dopamine systems.
Study at a glance
| Characteristics | In vitro and in silico study Peer reviewed |
|---|---|
| Population | Rat striatal sections and accumbens slices |
| Interventions | Diphenidine 2-methoxydiphenidine |
| Topics | Addiction |
| Keywords | Dat Autoradiography Brain Diphenidine |
| Key finding | Diphenidine increases dopamine efflux by binding to the dopamine transporter, whereas methoxphenidine has no significant effect on dopamine transporter binding or evoked dopamine release. |
Abstract
Novel psychoactive substances (NPS) may have unsuspected addiction potential through possessing stimulant properties. Stimulants normally act at the dopamine transporter (DAT) and thus increase dopamine (DA) availability in the brain, including nucleus accumbens, within the reward and addiction pathway. This paper aims to assess DAT responses to dissociative diarylethylamine NPS by means of in vitro and in silico approaches. We compared diphenidine (DPH) and 2-methoxydiphenidine (methoxphenidine, 2-MXP/MXP) for their binding to rat DAT, using autoradiography assessment of [125I]RTI-121 displacement in rat striatal sections. The drugs' effects on electrically-evoked DA efflux were measured by means of fast cyclic voltammetry in rat accumbens slices. Computational modeling, molecular dynamics and alchemical free energy simulations were used to analyse the atomistic changes within DAT in response to each of the five dissociatives: DPH, 2-MXP, 3-MXP, 4-MXP and 2-Cl-DPH, and to calculate their relative binding free energy. DPH increased DA efflux as a result of its binding to DAT, whereas MXP had no significant effect on either DAT binding or evoked DA efflux. Our computational findings corroborate the above and explain the conformational responses and atomistic processes within DAT during its interactions with the dissociative NPS. We suggest DPH can have addictive liability, unlike MXP, despite the chemical similarities of these two NPS.